Publicação científica trimestral do CREMERJ - volume 2 - número 2 - 2023

24 Doença do Refluxo Gastroesofágico Luiz J. Abrahão Junior Med. Ciên. e Arte , Rio de Janeiro, v.2, n.2, p.13-24, abr-jun 2023 26. Ashida K, Sakurai Y, Nishimura A, et al. Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis. Aliment Pharmacol Ther 2015;42(6):685-95, doi:10.1111/apt.13331 27. Ashida K, Sakurai Y, Hori T, et al. Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Aliment Pharmacol Ther 2016;43(2):240- 51, doi:10.1111/apt.13461 28. Moraes-Filho JP, Navarro-Rodriguez T, Barbuti R, et al. Guidelines for the diagnosis and management of gastroesophageal reflux disease: an evidence-based consensus. Arq Gastroenterol 2010;47(1):99-115, doi:10.1590/s0004-28032010000100017